The Potential Immunoregulatory Roles of Vitamin D in Neuromyelitis Optica Spectrum Disorder

被引:3
作者
Wu, Yifan [1 ]
Cai, Yu [1 ]
Liu, Mingyuan [2 ]
Zhu, Desheng [1 ]
Guan, Yangtai [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurol, 127 Pujian Rd, Shanghai 200127, Peoples R China
[2] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese Med & West, Dept Neurol, 110 Ganhe Rd, Shanghai 200437, Peoples R China
关键词
neuromyelitis optica spectrum disorder; NMOSD; vitamin D; immunoregulation; autoimmunity; MULTIPLE-SCLEROSIS PATIENTS; 4-SPECIFIC T-CELLS; D-BINDING PROTEIN; 1,25-DIHYDROXYVITAMIN D-3; CLINICAL-FEATURES; CONTROLLED-TRIAL; DISEASE COURSE; IGG PREDICTS; DOUBLE-BLIND; SUPPLEMENTATION;
D O I
10.1016/j.mscard.2020.102156
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Neuromyelitis optica spectrum disorder (NMOSD) is an autoantibody-mediated disease affecting the central nervous system (CNS). Its pathogenesis involves both innate and acquired immune reactions; specific antibody (Aquaporin-4 antibody) and inflammatory cells cause direct damage on lesion sites, while B cell-T cell interactions facilitate the demyelination. However, its etiology is still not fully understood. Vitamin D deficiency is present in numerous autoimmune diseases, including NMOSD. Evidence suggests that low vitamin D levels mayassociate with disease activity and relapse rate in NMOSD, indicating the participation in the pathogenesis of NMOSD. The immunoregulatory roles of vitamin D in both numerous autoimmune diseases and experimental autoimmune encephalomyelitis (EAE) models are increasingly recognized. Recent studies have revealed vitamin D modulation in cytokine production, immune cell development and differentiation, as well as antibody production. By enhancing an anti-inflammatory environment and suppressing the over-activated autoimmune process, vitamin D shows its potential immunoregulatory roles in NMOSD, which could possibly introduce a new therapy for NMOSD patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Pediatric Neuromyelitis Optica Spectrum Disorder
    Poisson, Kelsey
    Moeller, Karen
    Fisher, Kristen S.
    SEMINARS IN PEDIATRIC NEUROLOGY, 2023, 46 : 1 - 8
  • [2] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [3] Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments
    Du, Yi
    Li, Kaijun
    Liu, Wei
    Song, Ruitong
    Luo, Meifeng
    He, Jianfeng
    Xu, Xiaoyu
    Qu, Xiaosheng
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (04) : 272 - 279
  • [4] Neuromyelitis optica spectrum disorder: an overview
    Ramakrishnan, Pooja
    Nagarajan, Devipriya
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2020, 80 (03) : 256 - 272
  • [5] Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Lucchinetti, Claudia F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (07) : 631 - 639
  • [6] Low Levels of Vitamin D in Neuromyelitis Optica Spectrum Disorder: Association with Disease Disability
    Min, Ju-Hong
    Waters, Patrick
    Vincent, Angela
    Cho, Hye-Jin
    Joo, Byung-Euk
    Woo, Sook-Young
    Lee, Soo-Youn
    Shin, Hee-Young
    Lee, Kwang Ho
    Kim, Byoung Joon
    PLOS ONE, 2014, 9 (09):
  • [7] Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
    Wallach, Asya Izraelit
    Tremblay, Matthew
    Kister, Ilya
    NEUROLOGIC CLINICS, 2021, 39 (01) : 35 - 49
  • [8] Eculizumab in the treatment of neuromyelitis optica spectrum disorder
    Giglhuber, Katrin
    Berthele, Achim
    IMMUNOTHERAPY, 2020, 12 (14) : 1053 - 1066
  • [9] New therapies for neuromyelitis optica spectrum disorder
    Levy, Michael
    Fujihara, Kazuo
    Palace, Jacqueline
    LANCET NEUROLOGY, 2021, 20 (01) : 60 - 67
  • [10] Neuromyelitis optica spectrum disorder and menstruation
    Badihian, Sheruin
    Manouchehri, Navid
    Mirmosayyeb, Omid
    Ashtari, Fereshteh
    Shaygannejad, Vahid
    REVUE NEUROLOGIQUE, 2018, 174 (10) : 716 - 721